Already, clinical trials testing the efficacy of MET inhibitors in METΔexon14-presenting tumours have identified amplification and/or activating mutations in the KRAS or BRAF genes (as well as activating mutations in the PI3K-AKT pathway) to be a common form of acquired resistance [23,24,25,54,55]. This evidence concerns the gene MET and neoplasm.